Literature DB >> 1901207

The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)

M P Boland1, R J Knox, J J Roberts.   

Abstract

DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2) isolated from Walker 256 rat carcinoma cells can convert CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) to a cytotoxic DNA interstrand cross-linking agent. This is achieved by reduction of the 4-nitro group of CB 1954 to produce the hydroxylamino species, a bioactivation which accounts for the much greater sensitivity of Walker cells to CB 1954 when compared with other cells which are unable to carry out this reduction (Knox et al., Biochem Pharmacol 37: 4661-4669 and 4671-4677, 1988). As predicted from their measured DT diaphorase activities a number of rat hepatoma and hepatocyte cell lines were also shown to be sensitive to CB 1954. However, no CB 1954-sensitive cell lines of human origin were found, although levels of DT diaphorase similar to those in the sensitive rat cells were present in these cells. The human cells were as sensitive as rat cells to the active form of CB 1954 (5-(aziridin-1-yl)-4-hydroxyla mino-2-nitrobenzamide). DT diaphorase, purified to homogeneity from human Hep G2 cells, did metabolize CB 1954 to this 4-hydroxylamino product, but the rate of CB 1954 reduction and thus production of the cytotoxic product, was much lower than that of purified Walker enzyme (ratio of Kcat = 6.4). In addition, CB 1954 could be considered an inhibitor of, rather than a substrate for, the human form of DT diaphorase. The purified rat and human DT diaphorases possessed otherwise similar biochemical and molecular properties. These findings explain the decreased sensitivity towards CB 1954 of human cell lines when compared to rat cell lines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901207     DOI: 10.1016/0006-2952(91)90190-g

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.

Authors:  D L Gustafson; H D Beall; E M Bolton; D Ross; C A Waldren
Journal:  Mol Pharmacol       Date:  1996-10       Impact factor: 4.436

3.  Prodrugs in Cancer Chemotherapy.

Authors:  Richard J Knox; Tom A Connors
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

4.  Modulation of nitro-fatty acid signaling: prostaglandin reductase-1 is a nitroalkene reductase.

Authors:  Dario A Vitturi; Chen-Shan Chen; Steven R Woodcock; Sonia R Salvatore; Gustavo Bonacci; Jeffrey R Koenitzer; Nicolas A Stewart; Nobunao Wakabayashi; Thomas W Kensler; Bruce A Freeman; Francisco J Schopfer
Journal:  J Biol Chem       Date:  2013-07-22       Impact factor: 5.157

Review 5.  DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Authors:  D Ross; D Siegel; H Beall; A S Prakash; R T Mulcahy; N W Gibson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 6.  The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  R J Knox; F Friedlos; M P Boland
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

7.  Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites.

Authors:  Belinda S Hall; Christopher Bot; Shane R Wilkinson
Journal:  J Biol Chem       Date:  2011-02-23       Impact factor: 5.157

8.  DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?

Authors:  E Smitskamp-Wilms; G Giaccone; H M Pinedo; B F van der Laan; G J Peters
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

9.  2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

Authors:  N A Helsby; D M Ferry; A V Patterson; S M Pullen; W R Wilson
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

10.  Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

Authors:  D R Newell; K M Searle; N B Westwood; S S Burtles
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.